0.00

100.00% -7.539

Kintara Therapeutics Inc (KTRA)

Overview News Price History Financials Why KTRA Down? Discussions Forecast Stock Split

Kintara Therapeutics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Previous Close:

$7.539

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$11.99M

Revenue:

Net Income/Loss:

$-10.58M

P/E Ratio:

0.00

EPS:

-9.49

Net Cash Flow:

$-6.79M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$14.59

Kintara Therapeutics Inc Stock (KTRA) Company Profile

Name

Kintara Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (668)

Phone

(858) 350-4364

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 150, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

KTRA's Discussions on Twitter

Compare KTRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTRA Kintara Therapeutics Inc	0.00	11.99M	0	-10.58M	-6.79M	-5.96
VRTX Vertex Pharmaceuticals Inc	408.18	105.12B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	714.47	78.51B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	629.99	37.67B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	243.25	31.37B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.13	27.36B	3.30B	-501.07M	1.03B	-2.1146

Kintara Therapeutics Inc Stock (KTRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Initiated	Rodman & Renshaw	Buy
Nov-05-24	Initiated	Maxim Group	Buy

Kintara Therapeutics Inc Stock (KTRA) Latest News

Dec 11, 2024

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - The Eastern Progress Online

Dec 11, 2024

Nov 25, 2024

TuHURA Biosciences expects to complete enrollment for REM-001 study in Q4 - TipRanks

Nov 25, 2024

TuHURA Biosciences Advances Phase 3 Trial, Secures $36M Funding for Cancer Pipeline - StockTitan

Nov 25, 2024

Nov 14, 2024

TuHURA Biosciences Inc (HURA) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Oct 21, 2024

Kintara stock climbs 10% on TuHURA merger update - MSN

Oct 21, 2024

Can Kintara Therapeutics Inc (KTRA) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver

Oct 21, 2024

Oct 19, 2024

TuHURA Biosciences finalizes merger, sets Phase 3 trial - Investing.com India

Oct 19, 2024

Oct 18, 2024

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - PR Newswire

Oct 18, 2024

HURA Stock Price and Chart — NASDAQ:HURA - TradingView

Oct 18, 2024

Lowenstein Represents Kintara Therapeutics in Merger with TuHURA Biosciences - Lowenstein Sandler LLP

Oct 18, 2024

Oct 17, 2024

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics - AccessWire

Oct 17, 2024

Kintara approves 1-for-35 reverse stock split before merger - Investing.com India

Oct 17, 2024

Oct 16, 2024

Kintara Therapeutics Announces Stock Split Amid Merger - TipRanks

Oct 16, 2024

Kintara approves reverse stock split, rebrands as TuHURA Biosciences - Investing.com India

Oct 16, 2024

Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger - TipRanks

Oct 16, 2024

Kintara approves 1-for-35 reverse stock split before merger By Investing.com - Investing.com South Africa

Oct 16, 2024

Kintara approves reverse stock split, rebrands as TuHURA Biosciences By Investing.com - Investing.com Australia

Oct 16, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow

Oct 16, 2024